Noni Ella Winkler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Noni Ella Winkler has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Archana Koirala
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
3 shared publications - Kristine Macartney
The University of Sydney Children's Hospital Westmead Clinical School, Westmead, New South Wales, Australia
3 shared publications David O Irving
Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia
2 shared publicationsDominic E Dwyer
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
2 shared publicationsGuddu Kaur
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Westmead, New South Wales, Australia
2 shared publicationsIain B Gosbell
Australian Red Cross Lifeblood, Alexandria, New South Wales, Australia
2 shared publications
Latest Publications
- Open Access
Seroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study
Objectives: In 2022, Japanese encephalitis virus (JEV) was detected in humans and animals across mainland Australia. We examined the prevalence of JEV and endemic flaviviruses, Murray Valley encephalitis virus (MVEV) and Kunjin virus (KUNV) antibodies in blood donors in different risk geographic areas across southern Australia. Design: Prospective cross-sectional serosurvey for JEV, MVEV and KUNV-specific antibodies. Setting: Southern Australia. Participants: All Australian blood donors who attended nine high-risk (geographical proximity to recent human, animal and/or vector detections of JEV) and three low-risk (no competent JEV vector and no animal or human detections were nearby) donor centres between 8–26 August or 12–17 September 2022 were analysed. Primary and secondary outcome measures: Seroprevalence estimates of JEV, MVEV and KUNV-specific antibodies were compared between blood donors from collection sites in areas considered high-risk and low-risk for JEV infection. Seroprevalence estimates were adjusted for age and sex after excluding donors born in JEV-endemic countries and those with documented JEV vaccination. Results: JEV-specific antibody seroprevalence was 1.6% (95% CI 1.3% to 2.0%) from 5257 samples. Odds of JEV seropositivity were greater in high-risk versus low-risk areas (OR 1.8, 95% CI 1.5 to 2.2; absolute risk difference: 0.8 percentage points) and in males versus females (OR 2.1, 95% CI 1.2 to 3.6). In high-risk areas, people ≥70 years had higher seroprevalences than those aged 18–29 (OR 3.1, 95% CI 1.8 to 5.5). MVEV and KUNV-specific antibody seroprevalence were 2.2% (95% CI 1.9% to 2.7%) and 3.7% (95% CI 3.2% to 4.3%), respectively, with higher prevalence in high-risk areas (MVEV OR 2.6, 95% CI 1.6 to 4.3; KUNV OR 2.4, 95% CI 1.9 to 3.0) and older ages. Conclusions: Blood donors in areas where JEV emerged in the 2021–2022 Australian summer had a 0.8 percentage point higher seroprevalence compared with non-JEV transmission areas, with older male donors most likely to be seropositive. Patterns were similar for endemic flaviviruses. This data informed recommendations for JEV vaccine distribution to high-risk areas and the need for non-pharmaceutical mosquito prevention strategies across Australia, given the highly susceptible population.
Open AccessSeroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study
Objectives: In 2022, Japanese encephalitis virus (JEV) was detected in humans and animals across mainland Australia. We examined the prevalence of JEV and endemic flaviviruses, Murray Valley encephalitis virus (MVEV) and Kunjin virus (KUNV) antibodies in blood donors in different risk geographic areas across southern Australia. Design: Prospective cross-sectional serosurvey for JEV, MVEV and KUNV-specific antibodies. Setting: Southern Australia. Participants: All Australian blood donors who attended nine high-risk (geographical proximity to recent human, animal and/or vector detections of JEV) and three low-risk (no competent JEV vector and no animal or human detections were nearby) donor centres between 8–26 August or 12–17 September 2022 were analysed. Primary and secondary outcome measures: Seroprevalence estimates of JEV, MVEV and KUNV-specific antibodies were compared between blood donors from collection sites in areas considered high-risk and low-risk for JEV infection. Seroprevalence estimates were adjusted for age and sex after excluding donors born in JEV-endemic countries and those with documented JEV vaccination. Results: JEV-specific antibody seroprevalence was 1.6% (95% CI 1.3% to 2.0%) from 5257 samples. Odds of JEV seropositivity were greater in high-risk versus low-risk areas (OR 1.8, 95% CI 1.5 to 2.2; absolute risk difference: 0.8 percentage points) and in males versus females (OR 2.1, 95% CI 1.2 to 3.6). In high-risk areas, people ≥70 years had higher seroprevalences than those aged 18–29 (OR 3.1, 95% CI 1.8 to 5.5). MVEV and KUNV-specific antibody seroprevalence were 2.2% (95% CI 1.9% to 2.7%) and 3.7% (95% CI 3.2% to 4.3%), respectively, with higher prevalence in high-risk areas (MVEV OR 2.6, 95% CI 1.6 to 4.3; KUNV OR 2.4, 95% CI 1.9 to 3.0) and older ages. Conclusions: Blood donors in areas where JEV emerged in the 2021–2022 Australian summer had a 0.8 percentage point higher seroprevalence compared with non-JEV transmission areas, with older male donors most likely to be seropositive. Patterns were similar for endemic flaviviruses. This data informed recommendations for JEV vaccine distribution to high-risk areas and the need for non-pharmaceutical mosquito prevention strategies across Australia, given the highly susceptible population.
- Open Access
- 9 December 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (12) , e015585
Critical failings in humanitarian response: a cholera outbreak in Kumer Refugee Camp, Ethiopia, 2023
Cholera is an acute watery diarrhoeal disease caused by toxins from O1 and O139 serogroups of the bacteria vibrio cholerae.1 It causes an estimated 29 000–143 000 deaths each year worldwide.1 A national outbreak of cholera has been ongoing in Ethiopia since August 2022.2 In July 2023, a large point-source outbreak occurred in West Gondar, Ethiopia, involving over 2300 cases.3
- 9 December 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (12) , e015585
Open AccessCritical failings in humanitarian response: a cholera outbreak in Kumer Refugee Camp, Ethiopia, 2023
Cholera is an acute watery diarrhoeal disease caused by toxins from O1 and O139 serogroups of the bacteria vibrio cholerae.1 It causes an estimated 29 000–143 000 deaths each year worldwide.1 A national outbreak of cholera has been ongoing in Ethiopia since August 2022.2 In July 2023, a large point-source outbreak occurred in West Gondar, Ethiopia, involving over 2300 cases.3
- Open Access
Seroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread: protocol for a national cross-sectional study
Introduction Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors. Method Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses. Analysis Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model. Ethics National Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. Dissemination Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
Open AccessSeroprevalence of Japanese encephalitis virus-specific antibodies in Australia following novel epidemic spread: protocol for a national cross-sectional study
Introduction Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that causes encephalitis and other morbidity in Southeast Asia. Since February 2022, geographically dispersed JEV human, animal and vector detections occurred on the Australian mainland for the first time. This study will determine the prevalence of JEV-specific antibodies in human blood with a focus on populations at high risk of JEV exposure and determine risk factors associated with JEV seropositivity by location, age, occupation and other factors. Method Samples are collected using two approaches: from routine blood donors (4153 samples), and active collections targeting high-risk populations (convenience sampling). Consent-based sampling for the latter includes a participant questionnaire on demographic, vaccination and exposure data. Samples are tested for JEV-specific total antibody using a defined epitope-blocking ELISA, and total antibody to Australian endemic flaviviruses Murray Valley encephalitis and Kunjin viruses. Analysis Two analytic approaches will occur: descriptive estimates of seroprevalence and multivariable logistic regression using Bayesian hierarchical models. Descriptive analyses will include unadjusted analysis of raw data with exclusions for JEV-endemic country of birth, travel to JEV-endemic countries, prior JEV-vaccination, and sex-standardised and age-standardised analyses. Multivariable logistic regression will determine which risk factors are associated with JEV seropositivity likely due to recent transmission within Australia and the relative contribution of each factor when accounting for effects within the model. Ethics National Mutual Acceptance ethical approval was obtained from the Sydney Children’s Hospitals Network Human Research Ethics Committee (HREC). Local approvals were sought in each jurisdiction. Ethical approval was also obtained from the Australian Red Cross Lifeblood HREC. Dissemination Findings will be communicated to participants and their communities, and human and animal health stakeholders and policy-makers iteratively and after final analyses. Understanding human infection rates will inform procurement and targeted allocation of limited JEV vaccine, and public health strategies and communication campaigns, to at-risk populations.
- Open Access
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
SARS-CoV-2 Delta and Omicron variant transmission and the impact of vaccine in schools and child-care settings in Australia
Background: Over 214 million students globally have been affected by school closures during the COVID-19 pandemic. To address knowledge gaps on transmission of SARS-CoV-2 delta (B.1.617.2) and omicron (B.1.1.529) variants in educational settings we examined virus transmission in schools and early...
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Open AccessSARS-CoV-2 Delta and Omicron variant transmission and the impact of vaccine in schools and child-care settings in Australia
Background: Over 214 million students globally have been affected by school closures during the COVID-19 pandemic. To address knowledge gaps on transmission of SARS-CoV-2 delta (B.1.617.2) and omicron (B.1.1.529) variants in educational settings we examined virus transmission in schools and early...